GCM
ANIP icon

Graham Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Graham Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,710
Closed -$208K – 1244
2026
Q1 		$208K Sell
2,710
-3,197
-54% -$250K 0.01% 941
2025
Q4 		$466K Buy
5,907
+2,145
+57% +$186K 0.01% 647
2025
Q3 		$345K Sell
3,762
-6,124
-62% -$499K 0.01% 791
2025
Q2 		$645K Buy
9,886
+3,921
+66% +$255K 0.01% 718
2025
Q1 		$399K Sell
5,965
-393
-6% -$23.5K 0.01% 895
2024
Q4 		$351K Buy
+6,358
New +$365K 0.01% 866
2024
Q2 		– Sell
-3,334
Closed -$230K – 1028
2024
Q1 		$230K Sell
3,334
-1,763
-35% -$106K ﹤0.01% 863
2023
Q4 		$281K Sell
5,097
-6,869
-57% -$378K 0.01% 745
2023
Q3 		$695K Buy
11,966
+7,447
+165% +$430K 0.02% 463
2023
Q2 		$243K Buy
+4,519
New +$200K 0.01% 759
2023
Q1 		– Sell
-8,744
Closed -$352K – 1039
2022
Q4 		$352K Buy
+8,744
New +$328K 0.01% 850

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Graham Capital Management's ANIP Position: Q2 2026 in Review

Graham Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q2 2026, closing a stake of 2,710 shares — an estimated $208K sold.

Graham Capital Management first reported a position in ANIP in Q4 2022 and held it in 11 quarters. The position peaked at $695K in Q3 2023. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Graham Capital Management reported no remaining ANI Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Graham Capital Management sold 2,710 ANI Pharmaceuticals shares in Q2 2026, an estimated $208K.
  • Graham Capital Management first reported a position in ANI Pharmaceuticals in Q4 2022 and held it in 11 quarters.
  • Graham Capital Management's ANI Pharmaceuticals position peaked at $695K in Q3 2023.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.